Wednesday, May 25, 2016

No Pain, Only Gain For INNL, FDA Panel Backs SNY, Wait Continues For SRPT

Shares of Innocoll (INNL) rose as much as 70% on Wednesday, following positive results from two phase III pivotal studies evaluating XARACOLL as a postoperative pain relief treatment immediately following open abdominal hernia repair.

from RTT - Biotech http://ift.tt/1qKDTP3
via IFTTT

No comments:

Post a Comment